Histological Assessment of TA-GVHD
| Group5-150(n) . | Experiment . | Spleen . | Liver . | Bone Marrow . | Cheek . | Total . |
|---|---|---|---|---|---|---|
| Control (11) | 1 | 0 | 1 | 0 | 1 | 2 |
| 1 | 0 | 1 | 0 | 0 | 1 | |
| 1 | 0 | 0 | 0 | 0 | 0 | |
| 1 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 1 | 1 | 0 | 0 | 2 | |
| 2 | 1 | 1 | 0 | 0 | 2 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 3 | 1 | 0 | 0 | 1 | 2 | |
| 3 | 1 | 0 | 0 | 1 | 2 | |
| Mean ± SE | 0.4 ± 0.15 | 0.4 ± 0.15 | 0.0 ± 0.0 | 0.3 ± 0.15 | 1.0 ± 0.3 | |
| GVHD (6) | 1 | 3 | 2 | 2 | 2 | 9 |
| 1 | 3 | 3 | 2 | 3 | 11 | |
| 2 | 3 | 2 | 2 | 0 | 7 | |
| 2 | 3 | 3 | 2 | 1 | 9 | |
| 3 | 3 | 3 | 0 | 2 | 8 | |
| 3 | 3 | 3 | 2 | 2 | 10 | |
| Mean ± SE | 3.0 ± 0.0 | 2.7 ± 0.2 | 1.7 ± 0.3 | 1.7 ± 0.4 | 9.0 ± 0.6 | |
| Gamma (7) | 1 | 1 | 1 | 1 | 0 | 3 |
| 1 | 1 | 2 | 2 | 0 | 5 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 1 | 0 | 0 | 0 | 1 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 0 | 1 | 0 | 0 | 1 | |
| 3 | 1 | 0 | 0 | 0 | 1 | |
| Mean ± SE | 0.6 ± 0.2 | 0.6 ± 0.3 | 0.4 ± 0.3 | 0.0 ± 0 | 1.6 ± 0.7 | |
| PCT (6) | 1 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 1 | 0 | 0 | 0 | 1 | |
| 2 | 1 | 0 | 0 | 0 | 1 | |
| 2 | 1 | 0 | 0 | 1 | 2 | |
| 2 | 1 | 2 | 0 | 0 | 3 | |
| Mean ± SE | 0.7 ± 0.2 | 0.3 ± 0.3 | 0.0 ± 0.0 | 0.2 ± 0.2 | 1.2 ± 0.5 |
| Group5-150(n) . | Experiment . | Spleen . | Liver . | Bone Marrow . | Cheek . | Total . |
|---|---|---|---|---|---|---|
| Control (11) | 1 | 0 | 1 | 0 | 1 | 2 |
| 1 | 0 | 1 | 0 | 0 | 1 | |
| 1 | 0 | 0 | 0 | 0 | 0 | |
| 1 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 1 | 1 | 0 | 0 | 2 | |
| 2 | 1 | 1 | 0 | 0 | 2 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 3 | 1 | 0 | 0 | 1 | 2 | |
| 3 | 1 | 0 | 0 | 1 | 2 | |
| Mean ± SE | 0.4 ± 0.15 | 0.4 ± 0.15 | 0.0 ± 0.0 | 0.3 ± 0.15 | 1.0 ± 0.3 | |
| GVHD (6) | 1 | 3 | 2 | 2 | 2 | 9 |
| 1 | 3 | 3 | 2 | 3 | 11 | |
| 2 | 3 | 2 | 2 | 0 | 7 | |
| 2 | 3 | 3 | 2 | 1 | 9 | |
| 3 | 3 | 3 | 0 | 2 | 8 | |
| 3 | 3 | 3 | 2 | 2 | 10 | |
| Mean ± SE | 3.0 ± 0.0 | 2.7 ± 0.2 | 1.7 ± 0.3 | 1.7 ± 0.4 | 9.0 ± 0.6 | |
| Gamma (7) | 1 | 1 | 1 | 1 | 0 | 3 |
| 1 | 1 | 2 | 2 | 0 | 5 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 1 | 0 | 0 | 0 | 1 | |
| 2 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 0 | 1 | 0 | 0 | 1 | |
| 3 | 1 | 0 | 0 | 0 | 1 | |
| Mean ± SE | 0.6 ± 0.2 | 0.6 ± 0.3 | 0.4 ± 0.3 | 0.0 ± 0 | 1.6 ± 0.7 | |
| PCT (6) | 1 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | 0 | 0 | |
| 2 | 1 | 0 | 0 | 0 | 1 | |
| 2 | 1 | 0 | 0 | 0 | 1 | |
| 2 | 1 | 0 | 0 | 1 | 2 | |
| 2 | 1 | 2 | 0 | 0 | 3 | |
| Mean ± SE | 0.7 ± 0.2 | 0.3 ± 0.3 | 0.0 ± 0.0 | 0.2 ± 0.2 | 1.2 ± 0.5 |
Histologic assessment of TA-GVHD was performed for each treatment group.
Control, syngeneic control; GVHD, allogeneic control; Gamma, allogeneic, gamma radiation (2,500 cGy); PCT, allogeneic, S-59 (150 μmol/L) and UVA (2.1 J/cm2). The mean values and standard errors are indicated. The total number of mice in each group are indicated (n). The data were derived from three separate experiments (Table 3). The scoring system is shown in Table 2. The maximum possible score is 13.